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Background-—Obesity is key feature of the metabolic syndrome and is associated with high cardiovascular morbidity and mortality.
Obesity is associated with macrovascular endothelial dysfunction, a determinant of outcome in patients with coronary artery
disease. Here, we compared the inﬂuence of obesity on microvascular endothelial function to that of established cardiovascular
risk factors such as diabetes mellitus, hypertension, hypercholesterolemia, and smoking in patients with suspected coronary artery
disease.
Methods and Results-—Endothelial function was assessed during postocclusive reactive hyperemia of the brachial artery and
downstream microvascular beds in 108 patients who were scheduled for coronary angiography. In all patients, microvascular
vasodilation was assessed using peripheral arterial tonometry; laser Doppler ﬂowmetry and digital thermal monitoring were
performed. Body mass index was signiﬁcantly associated with decreased endothelium-dependent vasodilatation measured with
peripheral arterial tonometry (r=0.23, P=0.02), laser Doppler ﬂowmetry (r=0.30, P<0.01), and digital thermal monitoring (r=0.30,
P<0.01). In contrast, hypertension, hypercholesterolemia, and smoking had no inﬂuence on microvascular vasodilatation.
Especially in diabetic patients, endothelial function was not signiﬁcantly reduced (control versus diabetes mellitus, meanSEM or
median [interquartile range], peripheral arterial tonometry: 1.900.20 versus 1.670.20, P=0.19, laser Doppler ﬂowmetry: 728%
[interquartile range, 427–1110] versus 589% [interquartile range, 320–1067] P=0.28, and digital thermal monitoring: 6.61.0%
versus 2.51.7%, P=0.08). In multivariate linear regression analysis, body mass index was the only risk factor that signiﬁcantly
attenuated endothelium-dependent vasodilatation using all 3 microvascular function tests.
Conclusions-—Higher body mass index is associated with reduced endothelial function in patients with suspected coronary artery
disease, even after adjustment for treated diabetes mellitus, hypertension, hypercholesterolemia, and smoking. ( J Am Heart
Assoc. 2017;6:e006082. DOI: 10.1161/JAHA.117.006082.)
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D uring the past 3 decades, the prevalence of obesity hasnearly doubled worldwide and is still increasing.1
Obesity is closely related to the occurrence of glucose
intolerance, high blood pressure, dyslipidemia, and also
cardiovascular disease (CVD). Endothelial dysfunction is a
well-known early step in the pathogenesis of CVD.2,3
Endothelial function plays an important role in the regulation
of vascular tone, thrombosis, and smooth muscle cell
proliferation and when impaired, it can initiate and accelerate
progression of atherosclerosis.4,5
Endothelial function can be assessed with different meth-
ods that rely on the administration of stimuli of different
vasodilator pathways such as mechanical stress, thermal
provocation, electrical stimuli, or administration of vasoactive
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agents by iontophoresis.6 A blunted response is indicative of
endothelial dysfunction and predictive for CVD and clinical
prognosis.7–10
Only recently, the cutaneous microcirculation has emerged
as a clinically relevant model for microvascular reactivity and
endothelial function.6,11 In the microcirculation of the skin,
postocclusive reactive hyperemia triggers several pathways
for vascular reactivity. In addition to endothelial nitric oxide
synthase activity, sensory nerves and endothelium-derived
hyperpolarizing factors play an important role in the vasomo-
tor regulation of the microcirculation.12 Laser Doppler
ﬂowmetry (LDF) is frequently used to measure changes in
blood cell ﬂow (ﬂux) in the skin microcirculation after
endothelial stimulation.6 Recently, peripheral arterial tonom-
etry (EndoPAT; Itamar Medical Ltd, Caesarea, Israel) has
been developed to measure changes in pulse wave amplitude
within the ﬁngertip.13 A new method to assess microvascular
endothelial reactivity is digital thermal monitoring (DTM). By
monitoring the digital skin temperature overshoot during
hyperemia, vascular reactivity can be quantiﬁed.14
In the current study we aimed to determine the inﬂuence of
obesity on endothelial function compared with other compo-
nents of the metabolic syndrome and smoking in a population
of patients with suspected coronary artery disease. Endothe-
lial function was assessed simultaneously by LDF, EndoPAT,
and DTM, and its relationship to obesity as well as other
clinical risk factors and baseline characteristics was analyzed.
Methods
Study Design and Population
The study design was previously published and primarily
focused on the relationship between radial artery spasm and
endothelial function.15 In summary, patients at risk for
coronary disease and referred for elective cardiac catheter-
ization were eligible for study participation. Patients with ST-
segment elevation myocardial infarction or hemodynamic
instability or renal disease with a glomerular ﬁltration rate
<30 were excluded. Also, patients with an intention to
undergo transfemoral arterial access (ie, patients with coro-
nary bypass grafts) were excluded. Between May 2014 and
June 2015, patients were screened at the VU University
Medical Center. After obtaining informed consent, baseline
characteristics were noted. Also, a predeﬁned set of estab-
lished cardiovascular risk factors (diabetes mellitus, hyperc-
holesterolemia, hypertension, body mass index [BMI], age,
smoking, and sex) and cardiovascular history, were registered.
Thereafter, 3 different endothelial function tests were per-
formed at the same time and subsequently all patients
underwent coronary angiography. In this secondary analysis,
the relationship between BMI, other known cardiovascular
risk factors, and endothelial function was studied. The study
protocol was approved by the local ethics committee and
performed in accordance with the Declaration of Helsinki.
Endothelial Function Measurements
All endothelial function measurements were performed at the
same time by trained researchers in a quiet and temperature-
controlled room. The patients were resting during the entire
measurement period of 15 minutes. To determine postocclu-
sive reactive hyperemia, a blood pressure cuff was inﬂated at
the upper arm to a pressure at least 30 mm Hg above the
systolic arterial blood pressure. The microvascular measure-
ments were started 5 minutes before the occlusion period
and were stopped 5 minutes after the occlusion period
(during postocclusive reactive hyperemia). The maximum
hyperemic response is reached after 5 minutes of vascular
occlusion. This time point is recommended for EndoPAT
measurements.16
EndoPAT Measurements
The EndoPAT device (Itamar Medical Ltd) was used to
measure the arterial pulse wave amplitude with pneumatic
probes placed on the index ﬁnger of each hand, capable of
sensing volume changes in the digit with each arterial
pulsation. The contralateral hand was used as a reference
to correct for potential systemic changes. The ﬁngertip probes
have a rigid external casing containing inﬂatable chambers
with uniform applied pressure ﬁeld across the ﬁnger to
prevent venous pooling. Volume changes in the ﬁngertip were
recorded digitally as pulse amplitude that can be tracked over
time. Data are presented as Reactive Hyperemia Index (RHI);
this is the post-to-preocclusion PAT signal ratio in the
Clinical Perspective
What Is New?
• This observational study shows an association between
body mass index and endothelial function, even in patients
with treated metabolic risk factors.
What Are the Clinical Implications?
• Body mass index strongly inﬂuences endothelial function
throughout the spectrum of patients with and without
treated metabolic risk factors.
• This study sheds light on the relation of endothelial function
and the occurrence of metabolic disease in obese patients.
• Further studies are necessary to investigate the role of
endothelial dysfunction as a predictor of outcome in
patients with a high body mass index.
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occluded side, divided by the same ratio of the (nonoccluded)
control arm as a correction for possible systemic effects.17
Laser Doppler Flowmetry
Single-point LDF (Moor Instruments, Devon, UK) was mea-
sured at the upper phalanx of the right index ﬁnger. The signal
was quantiﬁed as the product of average blood cell velocity
and concentration. Because it does not provide an exact
measure of ﬂow (mL/min), ﬂux is often used.6 The ﬂux was
determined at baseline and the peak (5 minutes after cuff
deﬂation). Peak minus baseline and the percentage increase
between baseline and peak were calculated. This percentage
was used as a measure of endothelial function.
Digital Thermal Monitoring
Continuous DTM was performed during the entire measure-
ment of 15 minutes with the GOBI-1417 camera (XenICs NV,
Leuven, Belgium) at the distal phalanx of the thumb and the
proximal phalanx of the index ﬁnger (D2). DTM data were
expressed in temperature rebound (peak temperature minus
baseline temperature) compared with baseline temperature
(change in %).14
Statistical Analysis
Baseline characteristics are presented as percentage for
categorical variables and as mean SD in case of a normal
distribution and median (interquartile range, IQR) otherwise
for the continuous variables. The baseline table is divided into
3 BMI groups: normal (BMI <25), overweight (BMI 25–30), and
obese (BMI >30). Differences between these groups were
analyzed using v2 testing for categorical variables and ANOVA
for continuous variables. Test results are presented as
meanSEM or median in case of a skewed distribution.
Postocclusive reactive hyperemic values of each of the tests
(EndoPAT, LDF, DTM) were compared between groups based
on presence of risk factors using independent samples t tests
for normally distributed random variables and the Mann–
Whitney U test for variables that were not normally dis-
tributed. Separate comparisons were performed for each
endothelial test and risk factor. Normality was assessed using
separate QQ-plots of the postocclusive reactive hyperemic
values made in the subgroup with and without the risk factor.
All statistical tests were 2-tailed, and a P value of <0.05 was
considered as statistically signiﬁcant. Multivariate analyses
(linear regression) were performed for each endothelial
function test to relate the endothelial function measurement
to the 7 predeﬁned cardiovascular risk factors (age, sex,
diabetes mellitus, hypertension, hypercholesterolemia, smok-
ing, and BMI). Furthermore, to ﬁnd a set of independent risk
factors associated with endothelial function, a forward
selection procedure was used. Consistency of measurements
obtained with the 3 tests was quantiﬁed using Spearman’s
correlation coefﬁcient. All statistical analyses were performed
with SPSS for Windows version 22.0 (SPSS, Inc, Chicago, IL).
Results
A total of 796 patients referred for elective intervention were
screened from May 2014 to June 2015. Because of the time
burden of extensive endothelial testing, only 1 patient per day
(the ﬁrst in the morning) was asked to participate, resulting in
164 eligible patients with informed consent. In 35 patients,
not all endothelial tests could be performed because of
logistical reasons, leaving 129 patients with all 3 different
tests performed. Nineteen of the EndoPAT measurements and
2 of the LDF measurements were too noisy to analyze, leaving
108 of the 129 patients with all 3 tests available for the ﬁnal
analysis. The mean age of the study sample was 6311 years
and 68% of the patients were male. Of the female subjects,
the mean age was 6511 (ranging from 47 to 82 years) and
all women were presumed to be postmenopausal. Baseline
patient characteristics are presented in Table 1. The mean
postocclusive reactive hyperemia–induced vascular response
was 1.860.07% and 5.90.9% measured by RHI and DTM,
respectively (SEM). The LDF values had a skewed distribu-
tion and the median vascular response was 680% (IQR, 424–
1090). The Spearman correlation coefﬁcient between the 3
methods was 0.01 (P=0.32), 0.38 (P<0.01), and 0.26 (P=0.01)
for EndoPAT and DTM, EndoPAT and LDF, and LDF and DTM,
respectively.
BMI, Metabolic Risk Factors, and Endothelial
Function
There was a signiﬁcant correlation between BMI and
endothelial function as determined by all 3 tests (EndoPAT:
r=0.23, P = 0.02, LDF: r=0.30, P<0.01, and DTM:
r=0.30, P<0.01, Figures 1 and 2). None of the other
predeﬁned risk factors were related to a signiﬁcant decrease
in endothelial function in our population, especially the
metabolic risk factors (control compared with diabetes
mellitus: 1.900.20 versus 1.670.20, P=0.19, 728% [IQR
427–1110] versus 589% [IQR 320–1067] P=0.28, and
6.61.0% versus 2.51.7%, P=0.08). Control compared with
hypertension: 1.910.09 versus 1.800.10, P=0.42, 785%
(IQR 517–1349) versus 648% (IQR 391–1033) P=0.11, and
6.91.3% versus 4.51.0%, P=0.17. Control compared with
hypercholesterolemia: 1.840.08 versus 1.910.12, P=0.58,
668% (IQR 425–1046) versus 771% (IQR 384–1179) P=0.42,
and 7.11.2% versus 3.71.1%, P=0.06. In a linear
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multivariate analysis, using all predeﬁned risk factors in a
forward selection (sex, age, smoking, diabetes mellitus,
hypertension, hypercholesterolemia, and BMI), again only high
BMI was found to be associated with impaired endothelial
function (RHI: B=0.51, 95% CI [conﬁdence interval] [0.86,
0.15]; LDF: B=44, 95% CI [74, 14] and DTM: B=0.51,
95% CI [0.97, 0.05]). When all risk factors were combined
into a multivariable linear regression model, BMI still remained
independently related to endothelial function (Table 2).
Medication and Endothelial Function
The use of vasoactive medication had a minimal effect on the
test results (Table 3). Only patients using angiotensin-
converting enzyme inhibitor or angiotensin II receptor
inhibitors had signiﬁcantly reduced DTM (3.90.8% versus
8.21.6%, P=0.01) and in patients using calcium blocker, LDF
was reduced (588% [IQR 341–919] versus 785% [IQR 525–
1161], P=0.05). All other test results were not inﬂuenced by
the use of vasoactive medication. Also in patients without any
vasoactive drug (n=6), no difference in endothelial function
was found compared with patients on medication (2.050.22
versus 1.850.07, P=0.50, 804% [IQR 504–1968] versus
680% [IQR 423–1077], P=0.46, 8.44.3% versus 5.70.9%,
P=0.48 for RHI, LDF, and DTM, respectively). All patients with
hypertension or diabetes mellitus were medically treated for
this condition, and 90% of patients with hypercholesterolemia
received statin therapy.
Cardiovascular History, Coronary Artery Disease,
and Endothelial Function
Compared with patients with angiographic coronary artery
disease, deﬁned as >50% stenosis of a coronary segment
obtained by coronary angiogram after the endothelial function
tests, patients without previous or angiographic coronary
artery disease showed no difference in endothelial function
(RHI 1.920.07 versus 1.630.14, P=0.09, LDF 698% [IQR
426–1152] versus 582% [IQR 303–950] P=0.16, DTM
6.41.0% versus 4.01.2%, P=0.28). In comparison to
patients with stable coronary artery disease (n=80), patients
with the indication acute coronary syndrome (n=7) had
signiﬁcantly reduced values of endothelial function, as
measured with EndoPAT: 1.360.19 versus 1.970.08,
Table 1. Baseline Characteristics
Overall (n=108) BMI <25 (n=37) BMI 25 to 30 (n=43) BMI >30 (n=28)
Patient characteristics
Male, n (%) 73 (68) 21 (57) 31 (72) 21 (75)
Mean age (y) SD 6311 6311 6311 6310
Length (cm) SD 1759 17310 1769 17410
Weight (kg) SD 8316 699 849 10114*
BMI SD 274 231 271 333*
Systolic blood pressureSD 14021 13720 14119 14224
Diastolic blood pressureSD 7811 789 7911 7812
Cardiovascular history and coronary status
Previous MI, n (%) 21 (19) 8 (22) 7 (16) 6 (21)
Previous PCI, n (%) 31 (29) 8 (22) 12 (28) 11 (39)
PAD, n (%) 3 (3) 2 (5) 1 (2) 0 (0)
Indication ACS, n (%) 8 (7) 2 (5) 4 (9) 2 (7)
Angiographic CAD 80 (74%) 26 (70%) 33 (77%) 21 (75%)
No CHD history or angiographic CAD 21 (19%) 9 (24%) 8 (19%) 4 (14%)
Cardiovascular risk factors
Current smoking, n (%) 14 (13) 6 (16) 6 (14) 2 (7)
Diabetes mellitus, n (%) 18 (17) 0 (0) 4 (9) 14 (50)*
Hypertension, n (%) 47 (44) 14 (38) 15 (35) 18 (64)*
Hypercholesterolemia, n (%) 38 (35) 9 (24) 17 (40) 12 (43)
Differences between the 3 groups were analyzed using v2 testing for categorical variables and ANOVA for continuous variables. ACS indicates acute coronary syndrome; BMI, body mass
index; CAD, coronary artery disease; CHD, coronary heart disease; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention.
*P value for group difference <0.05.
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respectively, P=0.03, but not with the other endothelial
function tests.
Discussion
In our current study on patients with suspected signiﬁcant
coronary artery disease, BMI was independently and strongly
associated with microvascular endothelial dysfunction. Dia-
betes mellitus, hypertension, hypercholesterolemia, and
smoking did not signiﬁcantly inﬂuence endothelial function
in this population. In patients with a high BMI, a signiﬁcant
impairment of the hyperemic ﬂow response was found with all
3 microvascular endothelial function tests.
Several studies have been published reporting factors
inﬂuencing endothelial function. However, the outcomes vary
signiﬁcantly, possibly as a result of different study popula-
tions, different stimuli used for probing endothelial function,
and different methods used for analyzing vascular
response.18,19 Also several studies showed a high coefﬁcient
of variability when performing repeated measurements with
EndoPAT on the same day.20,21 LDF and DTM have lower
coefﬁcients of variability when same-day repeated testing is
done.14,22
Obese patients, especially those with visceral adiposity,
are known to have low-grade inﬂammation, which can lead to
insulin resistance and type 2 diabetes mellitus.23 Only
recently perivascular adipose tissue, which is increased in
obesity, has been shown to be of inﬂuence in microvascular
function. In addition to the lamina intima, media, and
adventitia, it is described as the fourth vessel wall layer,
Figure 1. Scatter plots of correlation BMI and RHI, ﬂux change (LDF), and temperature change (DTM). BMI indicates body mass index; DTM,
digital thermal monitoring; LDF, laser Doppler ﬂowmetry; RHI, Reactive Hyperemic Index.
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and this tissue has an important role in vasomotor regulation
by excreting vasoactive adipocytokines.24 Under normal
circumstances, perivascular adipose tissue functions in a
paracrine fashion, directly reducing smooth muscle tone25
and enhancing insulin-dependent vasodilatation. In obese
mice, perivascular adipose tissue–dependent vascular relax-
ation is attenuated, partly as a result of reduced nitric oxide
(NO) bioavailability.26,27 Change of perivascular adipose tissue
function in healthy obese women has been shown to lead to a
decreased insulin-dependent microvascular vasodilator capac-
ity,28 which in turn is linked to NO-dependent vasodilata-
tion.29 In 1 study, obese patients had a signiﬁcant lower
microvascular hyperemic response to postocclusive reactive
hyperemia compared with a healthy control population. This
difference diminished after lowering the BMI by gastric bypass
surgery, both in patients with and without type 2 diabetes
mellitus.30 In line with these results, our study showed that a
high BMI is an independent predictor of reduced endothelial
function in patients with suspected and established vascular
disease. Importantly, we have found that the relationship
between BMI and microvascular endothelial dysfunction
remains, even taking in account treated obesity-related
cardiometabolic risk factors such as hypertension, hyperc-
holesterolemia, and diabetes mellitus.
Not only is increased BMI a plausible cause for endothelial
dysfunction, but it has also been posed that endothelial
dysfunction itself may initiate other features of metabolic
syndrome. There is evidence that microvascular dysfunction
precedes insulin resistance, type 2 diabetes mellitus, and high
blood pressure.31–34
The weak correlation between the 3 tests in our study may
reﬂect the different entities of microvascular function. While
the peripheral arterial tonometry output is primarily deter-
mined by the effect of total increase of pulsatile arterial digital
blood volume (dilatation of arterioles), the output of the other
2 tests reﬂects changes in the capillary blood ﬂow of the
outer layer of the skin.35 The temperature of the skin is highly
dependent on skin capillary blood volume and might rather
reﬂect the (temperature) exchange capacity of the superﬁ-
cially located capillary endothelium than blood (cell) ﬂow in
Figure 2. Examples of microvascular endothelial test in a patient with high and low BMI: (A) representing a patient with a high BMI (34.9 kg/
m2) and (B) representing a patient with a low BMI (20.6 kg/m2). The red dotted line indicates time of occlusion, the green dotted line hyperemia.
Upper to lower panel: thermography (Ther) of the thumb followed by DTM, LDF, and PAT curves. BMI indicates body mass index; DTM, digital
thermal monitoring; LDF, laser Doppler ﬂowmetry; PAT, peripheral arterial tonometry.
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deeper situated arterioles as detected by LDF. Despite
different types of information obtained using these tests of
microvascular function, we have shown here that obesity
reduces microvascular responses measured with all tech-
niques, indicating that obesity impairs both arteriolar and
capillary function.
Table 2. Univariable and Multivariable Linear Regression With Microvascular Function as Dependent Variable (Separate for Each of
the 3 Tests)
Test Risk Factor Univariable b*
95% CI
P Value Multivariable b*
95% CI
P ValueLower Upper Lower Upper
PAT Female vs male 0.11 0.21 0.06 0.28 0.14 0.23 0.04 0.16
Age 0.16 0.24 0.02 0.11 0.20 0.28 0.00 0.05
Smoking 0.10 0.20 0.07 0.32 0.19 0.26 0.01 0.06
Diabetes mellitus 0.13 0.22 0.04 0.19 0.01 0.15 0.14 0.91
Hypertension 0.08 0.19 0.08 0.42 0.03 0.12 0.16 0.80
Hchol 0.05 0.10 0.17 0.58 0.11 0.05 0.21 0.24
BMI 0.23 0.29 0.03 0.02† 0.31 0.37 0.31 <0.01†
LDF Female vs male 0.03 0.22 0.16 0.77 0.09 163 59 0.35
Age 0.01 0.20 0.18 0.91 0.02 107 128 0.86
Smoking 0.04 0.22 0.16 0.66 0.03 127 96 0.78
Diabetes mellitus 0.09 0.15 0.27 0.28 0.06 86 160 0.56
Hypertension 0.20 0.35 0.03 0.11 0.16 210 27 0.13
Hchol 0.07 0.07 0.31 0.42 0.12 43 179 0.23
BMI 0.30 0.52 0.10 <0.01† 0.33 317 62 <0.01†
DTM Female vs male 0.19 0.0 3.4 0.05 0.13 0.5 2.9 0.17
Age 0.03 1.5 2.0 0.76 0.02 1.6 2.0 0.84
Smoking 0.03 2.0 1.5 0.79 0.06 2.3 1.2 0.51
Diabetes mellitus 0.17 3.2 0.2 0.08 0.02 2.0 1.8 0.88
Hypertension 0.14 2.9 0.5 0.17 0.07 2.4 1.2 0.51
Hchol 0.18 3.3 0.1 0.06 0.14 2.9 0.5 0.17
BMI 0.30 4.3 1.0 <0.01† 0.24 4.1 0.2 0.03†
BMI indicates body mass index; CI, conﬁdence interval; DTM, digital thermal monitoring; Hchol, hypercholesterolemia; LDF, laser Doppler ﬂowmetry; PAT, peripheral arterial tonometry.
*Linear regression is expressed as a standardized coefﬁcient. In the multivariable analyses, the coefﬁcients are corrected for all 6 other risk factors.
†Statistically signiﬁcant.
Table 3. Vasoactive Drugs and Endothelial Function
RHISEM P Value LDF (IQR) P Value DTMSEM P Value
ACE/ARB+ 1.890.10 0.65 646 (386–1044) 0.11 3.90.8 0.01*
ACE/ARB 1.830.09 835 (517–1428) 8.21.6
BBl+ 1.900.08 0.39 698 (423–1161) 0.54 5.61.1 0.58
BBl 1.770.11 649 (425–967) 6.71.3
CaBl+ 1.740.13 0.29 588 (341–919) 0.05* 4.71.1 0.38
CaBl 1.910.08 785 (525–1161) 6.41.1 0.05
Stat+ 1.870.08 0.85 677 (425–1052) 0.61 6.11.1 0.72
Stat 1.840.13 788 (367–1199) 5.31.3
Nitra+ 1.620.13 0.07 589 (326–908) 0.16 5.11.7 0.63
Nitra 1.930.08 770 (479–1139) 6.11.0
ACE/ARB indicates angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker; BBl, beat blocker; CaBl, calcium blocker; DTM, digital thermal monitoring; IQR, interquartile
range; LDF, laser Doppler ﬂowmetry; Nitra, long-acting nitrate; RHI, reactive hyperemia index; Stat, statin.
*Statistically signiﬁcant.
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Our population was small, heterogeneous, and consisted of
patients with and without established CVD. It is possible that
treatment of vascular disease and risk factors might have
inﬂuenced endothelial function. Indeed, most patients
received vasoactive medication at the time of the measure-
ments. However, the independent relation of BMI with
endothelium-dependent vasodilatation supports the hypothe-
sis that microvascular dysfunction is not reversed by treat-
ment of risk factors in obese patients and remains inﬂuenced
by adipose tissue, even in patients without diabetes mellitus
or other metabolic risk factors.28 The sample size may have
been too small to detect differences in endothelial function in
patients with and without metabolic risk factors. In particular,
comparison between groups based on risk factors with low
prevalence may have been limited by low power. For this
reason we also reported standardized regression coefﬁcients
that can be used to judge the strength of association of risk
factors with endothelium-dependent vasodilatation. Again BMI
and to a lesser extent diabetes mellitus and hypertension
showed small-to-moderate associations with endothelium-
dependent vasodilatation that were consistent for the 3 tests
used. In addition, there have been several small studies that
found a signiﬁcant inﬂuence of metabolic factors on endothe-
lial function.36,37 In our population, metabolic risk factors
were well treated, potentially obscuring the relation between
these risk factors and endothelial function.
In patients without established CVD, microvascular dys-
function potentially indicates a very early stage of atheroscle-
rosis and it might be the ﬁrst sign of cardiovascular risk, even
before the appearance of classical metabolic risk factors.
Especially in so-called metabolically healthy obese persons,
microvascular function testing might identify subjects at risk
for development of metabolic risk factors and cardiovascular
events. These apparently healthy persons may beneﬁt more
from early (lifestyle) intervention. Such intervention studies
are mandated and will shed light on the value of endothelial
function testing in addition to known metabolic risk factors.
Conclusion
High BMI is associated with endothelial dysfunction in
patients with suspected coronary artery disease, even in
patients with treated metabolic risk factors.
Disclosures
None.
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